New Delhi, January 12
Bharat Biotech today announced that it had signed an agreement with Precisa Medicamentos for the supplies of COVAXIN to Brazil.
A team from Precisa Medicamentos visited the Bharat Biotech facility last week to discuss potential export possibilities of COVAXIN, India’s first Indigenous vaccine for Covid-19.
In principle, it is understood between both parties that supplies of COVAXIN will be prioritised for the public market through a direct procurement by the Government of Brazil.
Supplies to the private market would be based upon receipt of market authorization from the Brazilian regulatory authority.
After the technical visit to Bharat Biotech’s Genome Valley facility in Hyderabad, the pharmaceutical director of Precisa Medicamentos, Emanuela Medrades said: “We identified highly technological, scientific and sanitary control levels. There were also excellent outcomes in clinical trials, which will be published soon. Bharat Biotech has exceeded our expectations, demonstrating quality and safety at the level of the largest vaccine suppliers in the world.” — TNS